Introduction
============

Hepatocellular carcinoma (HCC) is the fifth most prevalent malignant disease and the third leading cause of cancer-related death worldwide [@B1]-[@B3]. Surgical resection is currently considered as the only approach with curative potential for HCC patients [@B4], [@B5]. However, the prognosis of HCC patients after curative resection remains unsatisfactory due to high recurrence and metastasis incidence [@B6]-[@B8]. Thus, there is an urgent need for a reliable biomarker that can effectively detect patients with a poor prognosis so that additional treatments can be administered.

S100A9 is a calcium-binding protein that forms homodimers or heterodimers with S100A8 to play a vital role in inflammatory processes [@B9]-[@B11]. Previous studies have demonstrated that S100A9 is upregulated in several kinds of solid tumors, including colorectal [@B12], prostate [@B13], and breast cancer [@B14]. Importantly, overexpression of S100A9 has been found to be positively correlated with poor differentiation, tumor aggressiveness, metastasis, and worse clinical outcomes in these cancers [@B15]-[@B17], which has indicated its critical significance in mediating tumor progression. These findings suggest that S100A9 could serve as a promising biomarker for prognosis evaluation in cancer.

Previous investigations indicated that S100A9 was overexpressed in HCC tissues and could promote HCC cell growth and invasion through RAGE-dependent MAPK signaling cascades [@B18]-[@B20]. More importantly, systemic quantitative proteomics analysis showed that serum concentrations of S100A9, a secreted protein, were significantly upregulated in HCC patients, and these elevated levels showed satisfactory diagnostic potentials [@B21]. However, whether elevated serum S100A9 shows prognostic value has not been examined.

In light of the above findings, we designed a retrospective, single-center study with an independent validation cohort to investigate the prognostic potential of serum S100A9 in HCC patients receiving curative resection. We found that patients that encountered dismal outcomes showed significantly higher serum S100A9 levels. Our results indicate that serum S100A9 could serve as a novel, reliable, and promising circulating biomarker for prognosis evaluation in HCC.

Patients and Methods
====================

Study population
----------------

We retrospectively recruited 379 HCC patients who underwent curative resection at Ruijin Hospital (Jiaotong University, Shanghai, China) between January and December 2012. Patients were randomized into the training cohort (n=189) and validation cohort (n=190) (**Figure [1](#F1){ref-type="fig"}**). HCC was defined based on imaging scans and biochemistry tests and was confirmed by histopathology according to the American Association for the Study of Liver Diseases guidelines [@B22]. The HCC tumor stage was defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, and BCLC 0+A stage tumors were classified as early stage [@B23]. Tumor differentiation was determined according to the Edmondson grading system. Liver function was assessed by the Child-Pugh scoring system. Approval for the use of human subjects was obtained from the research ethics committee of Ruijin Hospital, and informed consent was obtained from each individual enrolled in the study.

Follow up
---------

Follow up was conducted according to the procedures of a previous study^24^. Briefly, patients were followed up every month during the first 6 months post-treatment and every 3 to 4 months thereafter. All patients were monitored by abdominal ultrasonography and chest X-ray every 1 to 6 months and by computed tomography scans every 6 months. Bone scans or magnetic resonance imaging scans were performed if localized bone pain was reported. Follow up ended in December 2017. Time to recurrence (TTR) was defined as the interval between surgery and the diagnosis of any type of recurrence, including intrahepatic or extrahepatic recurrence as identified by magnetic resonance imaging or computed tomography [@B24]. Overall survival (OS) was defined as the interval between treatment and death of any cause (months) or the last observation date [@B24].

Determination of serum S100A9 levels
------------------------------------

Pre-treatment serum (3 ml) was collected within 2 days before treatment for S100A9 concentration determination. Serum S100A9 was determined by enzyme-linked immunosorbent assay (ELISA) using the Human S100A9 ELISA Kit (Cusabio Biotech) according to the manufacturer\'s instructions. The detection range of the ELISA kit was 4.69-300 ng/ml, and serum samples beyond this range were further diluted before performing ELISA tests. The cutoff value of serum S100A9 level for diagnosis and prognosis was set at 252.40 ng/ml, according to the median value in the training cohort.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 20.0 software (IBM, Chicago, USA). Experimental values are presented as the mean ± SEM for continuous variables. χ^2^ tests, Fisher\'s exact probability tests and Student\'s *t*-tests were used for comparison between groups, as appropriate. If variances within groups were not homogeneous, the nonparametric Mann-Whitney *U* test or Wilcoxon signed-rank test was used. The prognostic value of S100A9 was evaluated by Kaplan-Meier survival curves, log-rank tests, and Cox proportional hazards models. A p-value less than 0.05 was considered significant.

Results
=======

Patient characteristics
-----------------------

The clinicopathologic characteristics of patients are shown in **Table [1](#T1){ref-type="table"}.** The mean patient age was 54.78 years (range: 25-82 years) in the training cohort, and 52.41 years (29-75 years) in the validation cohort. The major cause of liver disease was hepatitis B virus (HBV). All of the tumor characteristics except alpha-fetoprotein (AFP, ***P*=0.033**) were similar between the training and validation cohorts. During the follow-up period, 68.78% of patients (130/189) in the training cohort encountered recurrence, while 67.89% of patients (129/190) in the validation cohort encountered recurrence. Almost half (48.15%, 91/189) of the patients in the training cohort died during follow-up, and a similar rate of death was observed in the validation cohort (51.05%, 97/190).

Patient with advanced disease exhibited higher serum S100A9
-----------------------------------------------------------

In the training cohort, serum S100A9 concentrations were significantly higher in patients with advanced tumor stage (termed as BCLC stage B+C, 381.7±41.68 vs. 257.50±11.76, *P* \< 0.001, **Figure [2](#F2){ref-type="fig"}A**), poor differentiation (308.90±19.86 vs. 259.00±15.82, *P*=0.044, **Figure [2](#F2){ref-type="fig"}B**), multiple lesions (336.00±31.19 vs. 261.60±13.00, *P*=0.012, **Figure [2](#F2){ref-type="fig"}C**), and vascular invasion (302.00±21.88 vs. 268.80±15.05, *P*=0.042, **Figure [2](#F2){ref-type="fig"}D**). Similar results were observed in the validation cohort (all *P* \< 0.050, **Figure [2](#F2){ref-type="fig"}A-D**). Taken together, these findings suggested that serum S100A9 might be a potential indicator for reflecting the severity of HCC.

Serum S100A9 concentration was significantly elevated in patients who suffered poor outcome
-------------------------------------------------------------------------------------------

Next, we explored the correlation between serum S100A9 level and prognosis. In the training cohort, serum S100A9 level was significantly higher in recurrent patients than in non-recurrent patients (336.40±17.35 vs. 157.10±16.20, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}A**). Similarly, S100A9 level was significantly higher in patients who died during follow up than in those who were alive at the end of the study (333.30±14.75 vs. 227.70±18.39, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}B**).

In the validation cohort, we also observed significantly higher S100A9 levels in patients who suffered recurrence (288.80± 14.82 vs. 182.50±17.34, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}A**) and death (299.00±17.66 vs. 204.30±14.47, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}B**). These findings revealed that serum S100A9 could be used for predicting HCC prognosis.

Serum S100A9 served as a prognostic indicator in the training cohort
--------------------------------------------------------------------

We first investigated the prognostic significance of serum S100A9 in patients receiving curative resection in the training cohort. During the follow up, 68.78% of patients (130/189) encountered recurrence, and 48.15% (91/189) of patients died. Because there is no widely accepted cutoff value of serum S100A9 for predicting prognosis in HCC, we set the optimal cutoff value as 252.40 ng/ml, according to the median value in the training cohort, and stratified patients into two groups based on S100A9 level. We found that patients with higher serum S100A9 level had significantly shorter TTR (median 15.50 months vs. 64.00, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}C**) and OS (median 34.80 months vs. not reached, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}D**). Furthermore, ROC analysis were conducted to explore the performances of serum S100A9 for predicting prognosis in training cohort. Results showed that, in training cohort, AUC-ROC of S100A9 for predicting TTR and OS were 0.714 (Sensitivity 63.1%, Specificity 79.7%) and 0.656 (Sensitivity 65.9%, Specificity 65.3%), respectively (**Figure [3](#F3){ref-type="fig"}E, F**). While in validation cohort, AUC-ROC of S100A9 for predicting TTR and OS were 0.644 (Sensitivity 53.5%, Specificity 75.4%) and 0.659 (Sensitivity 59.8%, Specificity 72.0%), respectively (**Figure [3](#F3){ref-type="fig"}E, F**). The multivariate Cox regression analysis revealed that high serum S100A9 level before resection was a significant indicator for both TTR \[hazard ratio (HR): 2.315; 95% confidential interval (95% CI): 1.409-3.104; *P* \< 0.001; **Table [2](#T2){ref-type="table"}**\] and OS (HR: 2.081; 95% CI: 1.325-3.270;*P* \< 0.001, **Table [2](#T2){ref-type="table"}**).

Predicting prognosis of HCC patients with serum S100A9 level in subgroups of the training cohort
------------------------------------------------------------------------------------------------

The prognostic significance of serum S100A9 level within low recurrence/death risk subgroups was next investigated. Among patients with AFP ≤ 400 ng/ml (low-AFP), high serum S100A9 level indicated a higher probability of recurrence (median 17.45 months vs. not reached; *P* \< 0.001; **Figure [4](#F4){ref-type="fig"}A**) or death (median 39.21 months vs. not reached; *P* \< 0.001;**Figure [4](#F4){ref-type="fig"}A**). In the early-HCC subgroup, higher preoperative serum S100A9 level also indicated a significantly shorter TTR (median 19.77 months vs. not reached; *P* \< 0.001) or OS (38.50 months vs. not reached; *P* \< 0.001; **Figure [4](#F4){ref-type="fig"}B**). Additionally, serum S100A9 retained its prognostic value in patients without vascular invasion (TTR: median 17.40 months vs. not reached; *P* \< 0.001; OS: 36.00 months vs. not reached; *P* \< 0.001; **Figure [4](#F4){ref-type="fig"}C**) or small tumor (TTR: median 21.05 months vs not reached; *P* \< 0.001; OS: 51.63 months vs. not reached; *P* \< 0.001; **Figure [4](#F4){ref-type="fig"}D**).

Validation of serum S100A9 level as a prognostic indicator for HCC
------------------------------------------------------------------

To validate the prognostic value of serum S100A9, an independent cohort containing 190 HCC patients underwent curative resection was recruited. In the validation cohort, the TTR for patients with high serum S100A9 level was significantly shorter compared with those with low S100A9 level (median 14.75 months vs 44.75, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}C**). Patients with high serum S100A9 level also showed significantly shorter OS (median 32.50 months vs. not reached, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}D**). Multivariate Cox regression confirmed that high serum S100A9 level was an independent indicator for both TTR (HR 1.833; 95% 1.241-2.707; *P*=0.002; **Table [2](#T2){ref-type="table"}**) and OS (HR 1.948; 95% 1.250-3.035; *P*=0.003; **Table [2](#T2){ref-type="table"}**) in the validation cohort.

The prognostic value of serum S100A9 was also validated in low-recurrence/death-risk subgroups, and the results showed that serum S100A9 retained its prognostic value in the low-AFP subgroup (TTR: median 15.00 months vs. 45.33, *P*=0.009; OS: 38.75 vs. not reached, *P*=0.003; **Figure [4](#F4){ref-type="fig"}A**), early-stage (TTR: median 15.00 months vs. 49.83, *P* \< 0.001; OS: 38.50 vs. not reached, *P* \< 0.001; **Figure [4](#F4){ref-type="fig"}B**), no vascular invasion (TTR: median 14.00 months vs. 42.00, *P*=0.001; OS: 34.00 vs. not reached, *P*=0.005; **Figure [4](#F4){ref-type="fig"}C**), and small tumor size subgroups (TTR: median 16.50 months vs. 51.23, *P*=0.002; OS: 38.50 vs. not reached, *P* \< 0.001; **Figure [4](#F4){ref-type="fig"}D**). Collectively, our data successfully validated the prognostic value of serum S100A9 in HCC.

Correlation between serum S100A9 level and clinical characteristics
-------------------------------------------------------------------

In training cohort, patients with high serum S100 A9 level were prone to have a larger tumor than those with low S100A9 level (*P*=0.033, **Table [3](#T3){ref-type="table"}**). Moreover, patients with high serum S100A9 level were also likely to have multiple tumor lesions, though it did not reach statistical significance (*P*=0.051, **Table [3](#T3){ref-type="table"}**). However, there was no significant difference in other clinicopathological characteristics including pathological differentiation between high and low S100A9 level groups in the training cohort. Meanwhile, in validation cohort, high S100A9 level significantly correlated with multiple tumor numbers (*P*=0.014), vascular invasion (*P*=0.001), poor differentiation (*P*= 0.001), and advanced BCLC stage (*P*=0.037, **Table [3](#T3){ref-type="table"}**).

Discussion
==========

Determining HCC patients with high risk of developing recurrence remains a dilemma in current HCC surveillance, and few adjuvant treatment strategies are available for patients to help improve OS [@B25]. In the present study, we demonstrated the clinical significance of serum S100A9 in HCC. Our findings revealed that serum S100A9 was significantly elevated in HCC patients with dismal outcomes. Moreover, serum S100A9 was an independent predictor of both recurrence and death for HCC patients after curative resection, which was validated by an independent cohort of patients. Importantly, S100A9 retained its prognostic value in several conventional low-recurrence/death-risk subgroups, thereby strengthening the clinical utility of this circulating biomarker for predicting HCC prognosis.

Generally, recurrence of HCC is closely correlated with the invasiveness of tumor cells [@B26]-[@B28]. Tumor cells with high invasiveness potential could enter into the circulation, even in early-stage tumors, and spread to non-tumor liver tissues. These cells would then transform into quiescent conditions and would be susceptible to being triggered to develop recurrent lesions after curative resection [@B24]. S100A9 is considered to be one of the key regulators that contributes to tumor progression via triggering pro-tumor immune responses. Previous studies showed that stromal cells could secrete S100A9 to recruit myeloid cells to the tumor microenvironment, therefore resulting in an immunosuppressive status within the tumor microenvironment to promote tumor progression. Intriguingly, S100A9 was also reported as overexpressed in tumor cells, and tumor-derived S100A9 could function as a contributor for tumor migration and invasion, which inevitably leads to the metastasis of tumor cells [@B29], [@B30].

S100A9 was also proven as a critical contributor for HCC proliferation as well as invasion by activating ERK signaling, and *in situ* expression of S100A9 significantly correlated with poor prognosis of HCC patients [@B20]. Because S100A9 is a secreted protein, detection of serum S100A9 concentration might be a promising approach to distinguish patients with high risk of recurrence. Our data were well in line with previous findings showing that serum S100A9 was upregulated in HCC and patients with high preoperative S100A9 level showed significantly shorter TTR and OS [@B21]. Importantly, S100A9 level served as an independent indicator for dismal outcomes of HCC patients. Determination of S100A9 involves a serum-based methodology, which exhibits advantages in easy handling, cost effectiveness, and high reproducibility. Our results indicate S100A9 is a novel and reliable parameter for predicting prognosis after resection. Patients with high serum S100A9 should be paid more attention and more precise imaging scans should be applied to detect early recurrence. Moreover, adjuvant treatment might be applied to these patients to prevent recurrence.

In clinical practices, the prediction of individuals that will show poor outcome after curative resection for early-stage HCC has remained difficult [@B31]-[@B33]. We found that serum S100A9 level retained its clinical significance in BCLC 0+A-stage patients with HCC. Currently, AFP is the most widely used serum biomarker for HCC. However, approximately 30% to 40% of patients have normal serum AFP levels at diagnosis, which is a significant limitation for the clinical use of this biomarker. We investigated the prognostic value of S100A9 in the low-AFP subgroup and found that low-AFP patients could be stratified into two groups according to serum S100A9 with distinct outcomes. Our results suggested that S100A9 is a powerful prognostic marker for HCC, especially for patients with early-stage disease and normal AFP levels. These results indicate serum S100A9 as a novel serum biomarker for patients whose prognosis is difficult to predict by conventional indices.

There were several limitations in the present study. Most of our enrolled patients had HBV background, which means that the clinical significance needs to be further validated in patients with other etiology background [@B34]. In addition, the origin of high serum S100A9 also needs to be comprehensively investigated by histopathology assays. However, it should be noted that we constructed an independent cohort of patients to validate the clinical utility of serum S100A9, and the clinical characteristics between the training and validation cohorts were well balanced, which indicates the reliability and universality of our findings.

Conclusions
===========

To the best of our knowledge, this is the first report to demonstrate the prognostic prediction value of serum S100A9 in HCC patients. We confirmed that determination of serum S100A9 level might provide useful information to facilitate the implementation of different treatment approaches. Because the quantification of S100A9 in circulation is easy and reproducible using ELISA, it lends itself to wide applicability. Further investigation into the origin of S100A9 and its role in regulating the tumor microenvironment might provide a new insight into the mechanism of HCC recurrence and metastasis. This information may identify novel therapeutic strategies that target both the tumor cell itself and microenvironment to improve the prognosis of HCC patients.
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![**Correlation between serum S100A9 level and severity of HCC.** (A) Distribution of serum S100A9 levels in different BCLC stage of training (left) and validation (right) cohort. (B) Distribution of serum S100A9 levels in different Edmondson stage of training (left) and validation (right) cohort. (C) Distribution of serum S100A9 levels in patients with different tumor number of training (left) and validation (right) cohort. (D) Distribution of serum S100A9 levels in patients with or without vascular invasion of training (left) and validation (right) cohort.](jcav10p0408g002){#F2}

![**Serum S100A9 as an indicator for HCC prognosis after curative resection.** (A) Distribution of serum S100A9 levels in patient with different recurrence status of training (left) and validation (right) cohort. (B) Distribution of serum S100A9 levels in patient with different survival status of training (left) and validation (right) cohort. (C) Kaplan-Meier analysis of HCC patients according to serum S100A9 levels in training (left) and validation (right) cohort for predicting recurrence. (D) Kaplan-Meier analysis of HCC patients according to serum S100A9 levels in training (left) and validation (right) cohort for predicting overall survival. (E) ROC analysis of HCC patients according to serum S100A9 levels in training (left) and validation (right) cohort for predicting recurrence. (F) ROC analysis of HCC patients according to serum S100A9 levels in training (left) and validation (right) cohort for predicting time to overall survival.](jcav10p0408g003){#F3}

![**Serum S100A9 retained its prognostic value in low-recurrence-risk subgroups.** (A) Kaplan-Meier analysis of HCC patients with low-AFP (≤400ng/ml) according to serum S100A9 levels in training (left two graphs) and validation (right two graphs) cohort. (B) Kaplan-Meier analysis of HCC patients with early-HCC (BCLC 0+A) according to serum S100A9 levels in training (left two graphs) and validation (right two graphs) cohort. (C) Kaplan-Meier analysis of HCC patients without vascular invasion according to serum S100A9 levels in training (left two graphs) and validation (right two graphs) cohort. (D) Kaplan-Meier analysis of HCC patients with small-HCC (≤5cm) according to serum S100A9 levels in training (left two graphs) and validation (right two graphs) cohort.](jcav10p0408g004){#F4}

###### 

Patient characteristics in training and validation cohorts

  Characteristic          No. of patients   Training cohort   Validation cohort   *P*                     
  ----------------------- ----------------- ----------------- ------------------- ------- ------- ------- -----------
  Total No. of patients   379               189               190                                         
  Sex                     Male              323               167                 88.36   156     82.11   0.086
  Female                  56                22                11.64               34      17.89           
  Age                     ≤50               123               59                  31.21   64      33.68   0.608
  \>50                    256               130               68.79               126     66.32           
  AFP (ng/mL)             ≤400              249               134                 70.90   115     60.53   **0.033**
  \>400                   130               55                29.10               75      39.47           
  ALT (U/L)               ≤75               333               171                 90.48   162     85.26   0.120
  \>75                    46                18                9.52                28      14.74           
  Liver cirrhosis         No                64                37                  19.58   27      14.21   0.163
  Yes                     315               152               80.42               163     85.79           
  No.of tumor             Single            301               146                 77.25   155     81.58   0.297
  Multiple                78                43                22.75               35      18.42           
  Tumor size, cm          ≤5                230               111                 58.73   119     62.63   0.437
  \>5                     149               78                41.27               71      37.37           
  Vascular invasion       No                234               119                 62.96   115     60.53   0.626
  Yes                     145               70                37.04               75      39.47           
  Edmondson stage         I-II              229               115                 60.85   114     60.00   0.866
  III-IV                  150               74                39.15               76      40.00           
  Child-Pugh score        A                 364               184                 97.35   180     94.74   0.191
  B                       15                5                 2.65                10      5.26            
  BCLC stage              0+A               312               157                 83.07   155     81.58   0.704
  B+C                     87                32                16.93               35      18.42           

Abbreviations: AFP, α-fetoprotein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer

###### 

Multivariate Cox proportional hazard regression analysis of factors associate with prognosis in training and validation cohort

  --------------------------------------------------------------------------------------------------------------------------
  Characteristic           Training cohort   Validation cohort                                                 
  ------------------------ ----------------- ------------------- ------------- --------- ------- ------------- -------------
  **Indicators for TTR**                                                                                       

  AFP\                     \>400 vs          1.644               1.110-2.435   0.013     1.235   0.856-1.781   0.280
  (ng/mL)                                                                                                      

  ≤400                                                                                                         

  No.of tumor              Multiple vs       1.614               1.039-2.506   0.033     1.998   1.319-3.027   **0.001**

  Single                                                                                                       

  Tumor size\              \>5 vs            2.039               1.429-3.066   \<0.001   2.89    1.528-4.485   **\<0.001**
  (cm)                                                                                                         

  ≤5                                                                                                           

  Vascular invasion        Yse vs            1.226               0.840-1.788   0.290     N.A.                  

  No                                                                                                           

  Edmondson stage          III-IV vs         1.070               0.734-1.539   0.726     1.334   0.904-1.967   0.146

  I-II                                                                                                         

  Child-Puge stage         B vs              1.908               0.744-4.895   0.179     N.A.                  

  A                                                                                                            

  S100A9\                  ≤242.5 vs         2.315               1.409-3.104   \<0.001   1.833   1.241-2.707   **0.002**
  (ng/ml)                                                                                                      

  \>242.5                                                                                                      

  **Indicators for OS**                                                                                        

  AFP\                     \>400 vs          1.659               1.060-2.599   0.027     N.A.                  
  (ng/mL)                                                                                                      

  ≤400                                                                                                         

  No.of tumor              Multiple vs       1.770               1.093-2.867   0.002     2.195   1.390-3.465   **0.001**

  Single                                                                                                       

  Tumor size\              \>5 vs            2.056               1.320-3.202   0.001     1.712   1.128-2.597   **\<0.001**
  (cm)                                                                                                         

  ≤5                                                                                                           

  Vascular invasion        Yse vs            1.164               0.712-1.744   0.636     N.A.                  

  No                                                                                                           

  Child-Puge stage         B vs              2.413               0.840-6.930   0.102     1.061   0.425-2.650   0.899

  A                                                                                                            

  S100A9\                  ≤242.5 vs         2.081               1.325-3.270   \<0.001   1.948   1.250-3.035   **0.003**
  (ng/ml)                                                                                                      

  \>242.5                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------

Abbreviations: TTR, time to recurrence; OS, overall survival; AFP, α-fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer

###### 

Correlation between serum S100A9 and clinicopathological parameters

  ----------------------------------------------------------------------------------------------
  Characteristics     Training cohort        Validation cohort                           
  ------------------- ----------------- ---- ------------------- ------- ---- ----- ---- -------
  Sex                 Male              83   84                  0.669        87    69   0.990

  Female              12                10                       19      15              

  Age                 ≤50               25   34                  0.144        32    32   0.252

  \>50                70                60                       74      52              

  AFP\                ≤400              72   62                  0.137        68    47   0.251
  (ng/mL)                                                                                

  \>400               23                32                       38      37              

  ALT\                ≤75               87   84                  0.604        92    70   0.504
  (U/L)                                                                                  

  \>75                8                 10                       14      14              

  Liver cirrhosis     No                23   14                  0.107        15    12   0.979

  Yes                 72                80                       91      72              

  No.of tumor         Single            79   67                  0.051        93    62   0.014

  Multiple            16                27                       13      22              

  Tumor size, (cm)    ≤5                63   48                  0.033        69    50   0.431

  \>5                 32                46                       37      34              

  Vascular invasion   No                62   57                  0.510        77    38   0.001

  Yes                 33                37                       29      46              

  Edmondson stage     I-II              62   53                  0.211        78    36   0.001

  III-IV              33                41                       28      48              

  Child-Pugh score    A                 94   90                  0.170        100   80   0.783

  B                   1                 4                        6       4               

  BCLC stage          0+A               82   75                  0.231        92    63   0.037

  B+C                 13                19                       14      21              
  ----------------------------------------------------------------------------------------------

Abbreviations: AFP, α-fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer
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